Reference number : 172-2019-2020-Q1-926712, amendment number : , agreement type : C, recipient legal name : ME Therapeutics Inc., recipient country : CA, recipient province : BC, recipient city : North Hatley|North Hatley, recipient postal code : V7L 4B4, program name english : Industrial Research Assistance Program – Contributions to Firms, program name french : Programme d’aide à la recherche industrielle – Contributions aux entreprises, program purpose english : The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization, program purpose french : Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation, agreement title english : In vivo characterization of a novel cancer immunotherapeutic antibody, agreement title french : Caractérisation in vivo d'un nouvel anticorps immunothérapeutique contre le cancer, agreement number : 926712, agreement value : 82000.0, agreement start date : 2019-04-01, agreement end date : 2020-01-31, description english : The project will involve characterization of lead antibody product in in vivo cancer models to establish a robust efficacy profile., description french : Le projet portera sur la caractérisation du produit anticorps principal dans des modèles de cancer in vivo afin d'établir un profil d'efficacité robuste., expected results english : The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization, expected results french : Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation, additional information english : nan, additional information french : nan, owner organization : nrc-cnrc, owner organization title : National Research Council Canada | Conseil national de recherches Canada